Research Reference Only: All content on this page describes delivery methods and bioavailability data as documented in published preclinical research involving animal models and in vitro systems. This content is for research reference only and does not constitute guidance for human use or experimentation of any kind.
Intranasal Peptide Delivery in CNS Research Models
Published preclinical literature documents intranasal delivery as a CNS-targeted route for neuropeptide research in Wistar rat and murine CNS models, with Semax representing the most clinically validated intranasal peptide in this context.
Research Overview
Intranasal peptide delivery has been studied extensively as a strategy for bypassing the blood-brain barrier and achieving direct CNS distribution through the olfactory and trigeminal neural pathways. In Wistar rat CNS models, researchers have documented intranasal Semax delivery with associated BDNF and NGF upregulation in hippocampal and cortical tissue at short post-administration intervals. Murine ischemia models have utilized intranasal peptide delivery to study neuroprotective outcomes in MCAO paradigms, with this route providing CNS access without the systemic exposure associated with intravenous administration. Pinealon and NAD-plus research in rodent CNS paradigms has included intranasal delivery characterization studies, examining tissue distribution and gene expression outcomes in brain regions relevant to neuroprotection and aging.
Semax has been studied across the most extensive intranasal CNS delivery literature among peptide research compounds, spanning BDNF induction studies, ischemia neuroprotection models, and cognitive task performance paradigms in Wistar rats. The Russian clinical and regulatory approval of Semax as a nasal spray provides a pharmacological anchor for interpreting preclinical intranasal delivery data in the context of CNS-targeted peptide research.
Preclinical Bioavailability Data
Data from Published Preclinical Literature Only| Model | Compound | Finding | Source |
|---|---|---|---|
| Wistar rat hippocampal model | Semax | In Wistar rat models, intranasal Semax administration was documented to produce significant BDNF mRNA upregulation in hippocampal tissue within 1 to 3 hours of delivery, consistent with olfactory pathway CNS distribution and direct neurotrophic factor induction at the target tissue. | Institute of Molecular Genetics, Russian Academy of Sciences, multiple published studies |
| Wistar rat MCAO ischemia model | Semax | In middle cerebral artery occlusion rodent models in Wistar rats, intranasal Semax delivery was associated with reduced infarct volume and improved neurological deficit scores in treated animals relative to vehicle controls, attributed to BDNF induction and anti-inflammatory CNS signaling. | Neuroprotection literature, Russian preclinical ischemia series |
| Murine CNS model | Pinealon | Khavinson et al. examined intranasal and direct CNS delivery of Pinealon in murine neuronal models, documenting nuclear penetration in hippocampal cells and altered expression of neuronal survival genes consistent with the proposed chromatin interaction mechanism. | Khavinson et al., Institute of Bioregulation and Gerontology |
| Sprague-Dawley rat NAD model | NAD+ | Intranasal NAD-plus delivery in rodent CNS models has been examined for its capacity to restore neuronal NAD-plus levels and support PARP-dependent DNA repair in brain tissue, with published data documenting increased brain NAD-plus concentrations in Sprague-Dawley rats following intranasal delivery relative to systemic injection controls. | Neuronal NAD depletion and repletion research literature |
All data above describes findings from published preclinical animal model and in vitro research only. No human bioavailability data is presented or implied.
Stability and Handling in Research
In vitro stability characterization of Semax under simulated nasal mucosal conditions (pH 5.5 to 7.0, mucin-containing buffer, 37 degrees Celsius) has documented partial stability over 30 to 60 minute intervals, consistent with the short pharmacokinetic half-life observed in preclinical studies. NAD-plus stability in aqueous intranasal formulations has been assessed in buffer stability studies, with documented degradation at elevated temperatures and improved retention at 4 degrees Celsius storage conditions. Formulation studies examining peptide stability in mucosal delivery vehicles have employed hydroxypropyl methylcellulose and chitosan-based matrices to extend peptide residence time at the nasal epithelium in in vitro membrane permeation models.
All stability information above is derived from in vitro assay data and published analytical chemistry literature. This information describes laboratory characterization findings only.
Research Design Considerations
- 1
Olfactory versus trigeminal pathway distribution: Intranasal CNS delivery research must distinguish between olfactory bulb-mediated and trigeminal nerve-mediated CNS distribution pathways, as these routes access different brain regions and produce different tissue distribution profiles.
- 2
Volume and mucociliary clearance: Rodent intranasal delivery volumes of 5 to 20 microliters per nostril are documented in published protocols, with total volumes above this range associated with pulmonary aspiration in small rodent subjects.
- 3
Nasal mucosal absorption confirmation: Study designs should include brain tissue sampling at multiple timepoints post-delivery to confirm CNS distribution and distinguish nasal mucosal from olfactory nerve-mediated delivery.
- 4
Species-specific anatomy: The olfactory surface area in rodents is proportionally larger relative to body mass than in primates, which significantly enhances intranasal CNS access in rodent models and limits direct extrapolation of rodent intranasal bioavailability data.
Frequently Asked Questions
Continue Your Research
Explore the full Research Library for compound comparisons, use cases, and study indexes. All compounds available at minimum 98% HPLC-verified purity for in vitro research use only.
All compounds are strictly for in vitro research use only and not intended for human consumption.